Status epilepticus: A review of different syndromes, their current evaluation, and treatment

Neurologist

Volumn 9, Issue 2, 2003, Pages 61-76

  Gaitanis, John N ^a   Drislane, Frank W ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Antiepileptic drugs; Convulsions; Nonconvulsive status epilepticus; Seizure; Status epilepticus

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; DIAZEPAM; DIZOCILPINE; EXCITATORY AMINO ACID; FOSPHENYTOIN SODIUM; GABAPENTIN; GLUTAMATE RECEPTOR; GLUTAMIC ACID; KETAMINE; LAMOTRIGINE; LIDOCAINE; LORAZEPAM; MIDAZOLAM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXCARBAZEPINE; PENTOBARBITAL; PHENCYCLIDINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PROPOFOL; THIOPENTAL; UNINDEXED DRUG; VALPROIC ACID;

ASYSTOLE; ATAXIA; ATRIOVENTRICULAR BLOCK; AUTOREGULATION; BRAIN HYPOXIA; CARDIOPULMONARY ARREST; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMA; CONFUSION; DISEASE CLASSIFICATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAM; EPILEPTIC STATE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; ILEUS; MEDICAL DECISION MAKING; METABOLIC ACIDOSIS; MUSCLE WEAKNESS; NERVE CELL LESION; NERVE EXCITABILITY; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; OUTCOMES RESEARCH; PAIN; PATHOPHYSIOLOGY; PHLEBITIS; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; RHABDOMYOLYSIS; SEDATION; SHOCK; SIDE EFFECT; SKIN DISCOLORATION; SKIN EDEMA; SOFT TISSUE INJURY; STUPOR; TREATMENT PLANNING;

ANTICONVULSANTS; DRUG RESISTANCE; HUMANS; STATUS EPILEPTICUS; TERMINOLOGY;

EID: 0037346443     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nrl.0000051445.03160.2e     Document Type: Review

References (146)

1. Commission on Terminology of the International League Against Epilepsy. A proposed international classification of epileptic seizures. Epilepsia. 1964;5:297-306.
2. DeLorenzo RJ, Pellock JM, Towne AR, et al. Epidemiology of status epilepticus.j Clin Neurophysiol. 1995;12:316-325.
3. DeLorenzo RJ, Hauser WA, Towne AR, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 1996;46:1029-1035.
4. Logroscino G, Hesdorffer DC, Cascino G, Annegers JF, Hauser WA. Time trends in incidence, mortality, and case-fatality after first episode of status epilepticus. Epilepsia. 2001;42:1031-1035.
5. Rowan AJ, Scott DF. Major status epilepticus. Acta Neurol. Scand. 1970;46:573-584.
6. Celesia GG, Messert B, Murphy MJ. Status epilepticus of late adult onset. Neurology 1972;22:1047-1055.
7. Towne AR, Pellock JM, Ko D, et al. Determinants of mortality in status epilepticus. Epilepsia. 1994;35:27-34.
8. DeLorenzo RJ, Towne AR, Pellock JM, et al. Status epilepticus in children, adults, and the elderly. Epilepsia. 1992;33(suppl 4):15-25.
9. Wilson JVK, Reynolds EH. Translation and analysis of a cuneiform text forming part of a Babylonian treatise on epilepsy. Med Hist. 1990;34:185-198.
10. Calmeil J. De l'epilepsie, étudiée sous le rapport de son siege et de son influence sur la production de aliénation mentale. Université de Paris, 1824 (thesis).
11. Clark LP, Prout TP. Status epilepticus: a clinical and pathological study in epilepsy. Am J Insanity. 1904;60:645-699.
12. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for Revised Clinical and Electrographic Classification of Epileptic Seizures. Epilepsia. 1981;22:489-501.
13. Celesia GG. Modern concepts of status epilepticus. JAMA 1976;235:1571-1574.
14. Brodie M. Status epilepticus in adults. Lancet. 1990;336:551-552.
15. Meldrum BS, Brierley JB. Prolonged epileptic seizures in primates. Ischemic cell change and its relation to ictal physiological events. Arch Neurol. 1973;28:10-17.
16. Meldrum BS. Metabolic factors during prolonged seizures and their relation to nerve cell death. In: Delgado-Escueta AV, Wasterlain CG, Treiman DM, Porter RJ, eds. Advances in Neurology. Vol. 34, Status Epilepticus: Mechanisms of Brain Damage and Treatment. New York: Raven Press; 1983;261-275.
17. Nevander G, Ingvar M, Auer R, et al. Status epilepticus in well-oxygenated rats causes neuronal necrosis. Ann Neurol. 1985;18:281-290.
18. Meldrum BS. Epileptic brain damage: a consequence and a cause of seizures. Neuropathol Appl Neurobiol. 1997;17:7532-7540.
19. Lowenstein DH, Alldredge BK. Status epilepticus at an urban public hospital in the 1980s. Neurology. 1993;43:483-488.
20. Theodore WH, Porter RJ, Albert P, et al. The secondarily generalized tonic-clonic seizure: a videotape analysis. Neurology. 1994;44:1403-1407.
21. Kramer RE, Levinson PM. The duration of secondarily generalized seizures. Epilepsia. 1992;33(suppl 3):68(abs).
22. Shinnar S, Berg AT, Moshe SL, et al. How long do new-onset seizures in children last?. Ann Neurol. 2001;49:659-664.
23. 2+ sensitivity of hippocampal dentate granule cell GABA-A receptors. J Neurosci. 1997;17:7532-7540.
24. Bleck TP. Convulsive disorders: status epilepticus. Clin Neurophann. 1991;14:191-198.
25. Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med. 1998;339:792-798.
26. Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia. 1999;40:120-124.
27. Gastaut H. Classification of status epilepticus. In: Delgado-Escueta AV, Wasterlain CG, Treiman DM, Porter RJ, eds. Advances in Neurology, Vol. 34, Status Epilepticus: Mechanism of Brain Damage and Treatment. New York: Raven Press:1983;15-35.
28. Waterhouse EJ, DeLorenzo RJ. Status epilepticus in older patients: epidemiology, and treatment options. Drugs Aging. 2001;18:133-142.
29. Corey LA, Pellock JM, Boggs JG, et al. Evidence for a genetic predisposition for status epilepticus. Neurology. 1998;50:558-560.
30. Jumao-as A, Brenner RP. Myoclonic status epilepticus: a clinical and electroencephalographic study. Neurology. 1990;40:1199-1202.
31. Berkovic SF, Andermann F, Carpenter S, et al. Progressive myoclonus epilepsies: specific causes and diagnosis. N Engl J Med. 1986;315:296-305.
32. Young GB, Gilbert JJ, Zochodne DW. The significance of myoclonic status epilepticus in postanoxic coma. Neurology. 1990;40:1843-1848.
33. Celesia GG, Grigg MM, Ross E. Generalized status myoclonicus in acute anoxic and toxic-metabolic encephalopathies. Arch Neurol. 1988; 45:781-784.
34. DeLorenzo RJ, Waterhouse EJ, Towne AR, et al. Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia. 1998;39:833-840.
35. Kaplan PW. Nonconvulsive status epilepticus in the emergency room. Epilepsia. 1996;37:643-650.
36. Niedermeyer E, Khalifeh R. Petit mal status ("spike wave stupor"): an electroclinical appraisal. Epilepsia. 1965;6:250-262.
37. Andermann F, Robb JP. Absence status: a reappraisal following review of thirty-eight patients. Epilepsia. 1972;13:177-187.
38. Belafsky MA, Carwille S, Miller P, et al. Prolonged epileptic twilight states: continuous recordings with nasopharyngeal electrodes and videotape analysis. Neurology. 1978;28:239-245.
39. Engel J, Ludwig BI, Fetell M. Prolonged partial complex status epilepticus: EEG and behavioral observations. Neurology. 1978;28: 863-869.
40. Ballenger CE, King DW, Gallagher BB. Partial complex status epilepticus. Neurology. 1983;33:1545-1552.
41. Tassinari CA, Bureau M, Dravet C, et al. Epilepsy with continuous spikes and waves during slow sleep - otherwise described as ESES. Roger J, Bureau M, Dravet C, Dreifuss FE, Perret A, Wolf P. Epileptic Syndromes in Infancy, Childhood, and Adoloscence, 2nd Ed. London: John Libbey; 1992;245-256.
42. Galanopoulou AS, Bojko A, Lado F, et al. The spectrum of neuropsychiatric abnormalities associated with electrical status epilepticus in sleep. Brain Dev. 2000;22:279-295.
43. Tassinari CA, Rubboli L, Volpi S, et al. Encephalopathy with electrical status epilepticus during slow sleep or ESES syndrome including acquired aphasia. Clin Neurophysiol. 2000;111(Suppl 2):94-102.
44. Rousselle C, Revol M. Relations between cognitive functions and continuous spikes and waves during slow sleep. In: Beaumanoir A, Bureau M, Deonna T, Mira L, Tassinari CA. eds. Continuous Spikes and Waves During Slow Sleep: Acquired Epileptic Aphasia and Related Conditions. London: John Libbey; 1995;123-133.
45. Drislane FW, Schomer DL. Clinical implications of generalized electrographic status epilepticus. Epilepsy Res. 1994;19:111-121.
46. Thomas JE, Reagan TJ, Klass DW. Epilepsia partialis continua. A review of 32 cases. Arch Neurol. 1977;34:266-275.
47. Cockerell OC, Rothwell J, Thompson PD, et al. Clinical and physiological features of epilepsia partialis continua. Cases ascertained in the UK. Brain. 1996;119:393-407.
48. Drislane FW, Blum AS, Schomer DL. Focal status epilepticus: clinical features and significance of different EEG patterns. Epilepsia. 1999;40: 1254-1260.
49. Ghosh D, Mohanty G, Prabhakar S. Ictal deafness - a report of three cases. Seizure. 2001;10:130-133.
50. Hamilton NG, Matthews T. Aphasia: the sole manifestation of focal status epilepticus. Neurology. 1979;29:745-748.
51. Wells CR, Labar DR, Solomon GE. Aphasia as the sole manifestation of simple partial status epilepticus. Epilepsia. 1992;333:84-87.
52. Lothman EW. The biochemical basis and pathophysiology of status epilepticus. Neurology. 1990;40(suppl 2):13-23.
53. Lothman EW, Bertram EH, Stringer JL. Functional anatomy of hippocampal seizures. Prog Neurobiol. 1991;37:1-82.
54. Perl TM, Bedard L, Kosatsy T, et al. An outbreak of toxic encephalopathy caused by eating mussels contaminated with domoic acid. N Engl J Med. 1990;322:1775-1780.
55. Teitelbaum JS, Zatorre RJ, Carpenter S, et al. Neurologic sequelae of domoic acid intoxication due to the ingestion of contaminated mussels. N Engl J Med. 1990;322:1781-1787.
56. Lodge D, Collinridge G. Les agents provocateurs: a series on the pharmacology of excitatory amino acids. Trends Pharmacol Sci. 1990; 11:22-24.
57. Meldrum BS, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci. 1990;11:379-387.
58. Wasterlain CG, Fujikawa DG, Penix L. Pathophysiological mechanisms of brain damage from status epilepticus. Epilepsia. 1993; 34(suppl 1):37-53.
59. Lothman EW, Bertram EH. Epileptogenic effects of status epilepricus. Epilepsia. 1993;134(suppl 1):59-70.
60. DeGiorgio CM, Tomiyasu U, Gott PG, et al. Hippocampal pyramidal cell loss in human status epilepticus. Epilepsia. 1992;33:23-27.
61. Clifford DB, Olney JW, Benz AM, et al. Keramine, phencyclidine, and MK-801 protect against kainic acid-induced seizure-related brain damage. Epilepsia 1990;31:382-390.
62. Mycek M. Anxiolytic and hypnotic drugs. In: Mycek MJ, Harvey RA, Champe PC, eds. Pharmacology, 2nd Ed. Lippincott-Raven; 1997; 94-96.
63. Macdonald RL, McLean MJ. Anticonvulsant drugs: mechanisms of action. In: Delgado-Escueta AV. Ward AA Jr., Woodbury DM, Porter RJ, eds. Advances in Neurology, Vol. 44, Basic Mechanisms of the Epilepsies: Molecular and Cellular Approaches. New York. Raven Press; 1986;713-736.
64. Leppik IE. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 1983;249:1452-1454.
65. Alldredge BK, Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med. 2001;345:631-637.
66. Chiulli DA, Terndrup TE, Kanter RK. The influence of diazepam or lorazepam on the frequency of endotracheal intubation in childhood status epilepticus. J Emerg Med. 1991;9:13-17.
67. Pellock JM. Management of acute seizure episodes. Epilepsia. 1998; 39(suppl 1):28-35.
68. Diekmann RA. Rectal diazepam for prehospital pediatric status epilepticus. Ann Emerg Med. 1994;23:216-224.
69. Treiman DM. The role of benzodiazepines in the management of status epilepticus. Neurology. 19901;40(suppl 2):32-42.
70. Walker JE, Homan RW, Vasco MR, et al. Lorazepam in status epilepticus. Ann Neurol. 1979;6:207-213.
71. Holmes GL, Riviello JJ Jr. Midazolam and pentobarbital for refractory status epilepticus. Pediatr Neurol. 1999;20:259-264.
72. Smith BJ. Treatment of status epilepticus. Neurologic Clinics. 2001;19: 347-369.
73. Chamberlain JM, Altieri MA, Futterman C, et al. A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Pediatric Emerg Care. 1997;13:92-94.
74. Wallace SJ. Nasal benzodiazepines for management of acute childhood seizures? Lancet. 1997;349:222 (let).
75. Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet. 1999;353:623-626.
76. Koul RL, Raj Aithala G, Chacko A, et al. Continuous midazolam infusion as treatment of status epilepticus. Arch Dis Child. 1997;76: 445-448.
77. Osorio I, Reed RC. Treatment of refractory generalized tonic-clonic status epilepticus with pentobarbital aneththesia after high-dose phenytoin. Epilepsia. 1989;30:464-471.
78. Lowenstein DH, Alldredge BK. Status epilepticus. N Engl J Med. 1998;338:970-976.
79. Randazzo DN, Ciccone A, Schweitzer P, et al. Complete atrioventricular block with ventricular asystole following infusion of intravenous phenytoin. J Electiocardiol. 1995;28:157-159.
80. Burneo JG, Anandan JV, Barkley GL. A prospective study of the incidence of the purple glove syndrome. Epilepsia. 2001;42:1156-1159.
81. Wilder BJ. Use of parenteral antiepileptic drugs and the role of fosphenytoin. Neurology. 1996;46(suppl 1):1-2.
82. Browne TR, Kugler AR, Eldon MA. Pharmacology and pharmacokinetics of fosphenytoin. Neurology. 1996;46(suppl 1):3-7.
83. Touchette DR, Rhoney DH. Cost-minimization analysis of phenytoin and fosphenytoin in the emergency department. Pharmacotherapy. 2000;20:908-916.
84. Bleck TP. Management approaches to prolonged seizure and status epilepticus. Epilepsia. 1999;40(suppl 1):59-63.
85. Van Ness PC. Pentobarbital and EEG burst suppression in treatment of status epilepticus refractory to benzodiazepines and phenytoin. Epilepsia. 1990;31:61-67.
86. Krishnamurthy KB, Drislane FW. Depth of EEG suppression and outcome in barbiturate anesthetic treatment for refractory status epilepticus. Epilepsia. 1999;40:759-762.
87. Claassen J, Hirsch, Emerson RG, et al. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia. 2002;43:146-153.
88. Hodges BM, Mazur JE. Intravenous valproate in status epilepticus. Ann Pharmacother. 2001;35:1465-1470.
89. Chez MG, Hammer MS, Loeffel M, et al. Clinical experience of three pediatric and one adult case of spike-and-wave status epilepticus treated with injectable valproic acid. J Child Neurol. 1999;14:239-242.
90. Czapinski P, Terczynski A. Intravenous valproic acid administration in status epilepticus. Neurol Neurochir Pol. 1998;32:11-22.
91. Campistol J, Fernandez A, Ortega J. Status epilepticus in children. Experience with intravenous valproate. Update of treatment guidelines. Rev Neurol. 1999;29:359-365.
92. Sinha S, Naritoku DK. Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology. 2000;55:722-724.
93. Shorvon S. Tonic clonic status epilepticus. J Neurol Neurosurg Psychiatry. 1993;56:125-134.
94. Kuisma M, Roine RO. Propofol in prehospital treatment of convulsive status epilepticus. Epilepsia. 1995;36:1241-1243.
95. Prasad A, Worrall BB, Bertram EH, et al. Propofol and midazolam in the treatment of refractory status epilepticus. Epilepsia. 2001;42: 380-386.
96. Aicardi J, Chevrie JJ. Convulsive SE in infants and children: a study of 239 cases. Epilepsia. 1970;11:187-197.
97. DeLorenzo RJ, Garnett LK, Towne AR, et al. Comparison of status epilepticus with prolonged seizures episodes lasting from 10 to 29 minutes. Epilepsia. 1999;40:164-169.
98. Jordan KG. Status epilepticus: a perspective from the neuroscience intensive care unit. Neurosurg Clin N Am. 1994;5:679-680.
99. Alldredge BK, Wall DB, Ferriero DM. Effect of prehospital treatment on the outcome of status epilepticus in children. Ped Neurol. 1995;12: 213-216.
100. Lowenstein DH, Alldredge BK, Allen F, et al. The prehospital treatment of status epilepticus (PHTSE) study: design and methodology. Control Clin Trials. 2001;22:290-309.
101. Appleton R, Sweeney, A, Choonara I, et al. Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus. Dev Med Child Neurol. 1995;37:682-688.
102. Stecker MM, Kramer TH, Raps EC, et al. Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. Epilepsia. 1998;39:18-26.
103. Hanna JP, Ramundo ML. Rhabdomyolysis aud hypoxia associated with prolonged propofol infusion in children. Neurology. 1998;50: 301-303.
104. Rivera R, Segnini M, Baltodano A, et al. Midazolam in the treatment of status epilepticus in children. Crit Care Med. 1993;21:991-994.
105. Parent JM, Lowenstein DH. Treatment of refractory generalized status epilepticus with continuous infusion of midazolam. Neurology. 1994; 44:1837-1840.
106. Galdames Poblete D, Silva-Rosas C, Aguilera Olivares L. Treatment of status epilepticus with midazolam: report of four cases. Neurologia. 1994;9:109-111.
107. Crisp BC, Gannon R, Knauft F. Continuous infusion of midazolam hydrochloride to control status epilepticus. Clin Pharm. 1988;7: 322-324.
108. Kumar A, Bleck TP. Intravenous midazolam for the treatment of refractory status epilepticus. Crit Care Med. 1992;20:483-488.
109. Claassen J, Hirsch LJ, Emerson RG, et al. Continuous EEG monitoring and midazolam infusion for refractory, nonconvulsive status epilepticus. Neurology. 2001;57:1036-1042.
110. Yaffe K, Lowenstein DH. Prognostic factors for pentobarbital therapy for refractory generalized status epilepticus. Neurology. 1993;43: 895-900.
111. Krishnamurthy KB, Drislane FW. Relapse and survival after barbiturate anesthetic treatment of refractory status epilepticus. Epilepsia. 1996;37:863-867.
112. Archer LT, White GL, Beller-Todd B, et al. Does sodium pentobarbital anesthesia compromise phagocytosis of E. coli in vitro? Circ Shock. 1980;7:425-433.
113. Walker IA, Slovis CM. Lidocaine in the treatment of status epilepticus. Acad Emerg Med. 1997;4:918-922.
114. Sheth RD, Gidal BE. Refractory status epilepticus: response to ketamine. Neurology. 1998;51:1765-1766.
115. Winston KR, Levisohn P, Miller BR, et al. Vagal nerve stimulation for status epilepticus. Pediatr Neurosurg. 2001;34:190-192.
116. Lisanby SH, Bazil CW, Resor SR, et al. ECT in the treatment of status epilepticus. J ECT. 2001;17:210-215.
117. D'Giano CH, Del C Garcia M, Pomata H, et al. Treatment of refractory partial status epilepticus with multiple subpial transection: case report. Seizure. 2001;10:382-385.
118. Ma X, Liporace J, O'Connor MJ, et al. Neurosurgical treatment of medically intractable status epilepticus. Epilepsy Res. 2001;46:33-38.
119. Graves NM, Kriel RL, Jones-Saete C, et al. Relative bioavailability of rectally administered carbamazepine suspension in humans. Epilepsia. 1985;26:429-433.
120. Birnbaum AK, Kriel RL, Burkhardt RT, et al. Rectal absorption of lamotrigine compressed tablets. Epilepsia. 2000;41:850-853.
121. Kriel RL, Birnbaum AK, Cloyd JC, et al. Failure of absorption of gabapentin after rectal administration. Epilepsia. 1997;38:1242-1244.
122. van der Kuy PH, Koppejan EH, Wirtz JJ. Rectal absorption of oxcarbazepine. Pharm World Sci. 2000;22:165-166.
123. Guberman A, Cantu-Reyna G, Stuss D, et al. Nonconvulsive generalized status epilepticus: clinical features, neuropsychological testing, and long-term follow-up. Neurology. 1986;36:1284-1291.
124. Scholtes FB, Renier WO, Meinardi H. Non-convulsive status epilepticus, causes, treatment, and outcome in 65 patients. J. Neurol Neurosurg Psychiatry. 1996;61:93-95.
125. Thomas P, Beaumanoir A, Genton P, et al. 'De novo' absence status of late onset: report of 11 cases. Neurology. 1992;42:104-110.
126. Cockerell OC, Walker MC, Sander JWAS, et al. Complex partial status epilepticus: a recurrent problem. J Neurol Neurosurg Psychiatry. 1994;57:835-837.
127. So EL, Ruggles KH, Ahmann PA, et al. Clinical significance and outcome of subclinical status epilepticus in adults. J Epilepsy. 1995;8: 11-15.
128. Gurer G, Saygi S, Ciger A. Epilepsia partialis continua: clinical and electrophysiological features of adult patients. Clin Electroencephalogr. 2001;32:1-9.
129. Borchert LD, Labar DR. Permanent hemiparesis due to partial status epilepticus. Neurology. 1995;45:187-188.
130. Molyneux PD, Barker RA, Thom M, et al. Successful treatment of intractable epilepsia partialis continua with multiple subpial transections. J Neurol Neurosurg Psychiatry. 1998;65:137-138.
131. Hughes DR, Sharpe MD, McLachlan RS. Control of epilepsia partialis continua and secondarily generalized status epilepticus with isoflurane. J Neurol Neurosurg Psychiatry. 1992;55:739-740.
132. Rice AC, DeLorenzo RJ. N-methyl-D-aspartate receptor activation regulates refractoriness of status epilepticus to diazepam. Neuroscience. 1999;93:117-123.
133. Borris DJ, Bertram EH, Kapur J. Ketamine controls prolonged status epilepticus. Epilepsy Res. 2000;42:117-122.
134. Mazarati AM, Hohmann JG, Bacon A, et al. Modulation of hippocampal excitability and seizures by galanin. J Neurosci. 2000;20: 6276-6281.
135. Mazarati AM, Wasterlain CG, Sankar R, et al. Self-sustaining status epilepticus after brief electrical stimulation of the perforant path. Brain Res. 1998;801:251-253.
136. Mazarati AM, Halaszi E, Telegdy G. Anticonvulsive effects of galanin administered into the central nervous system upon the picrotoxin-kindled seizure syndrome in rats. Brain Res. 1992;589:164-166.
137. Vezzani A, Hoyer D. Brain somatostatin: a candidate inhibitory role in seizures and epileptogenesis. Eur J Neurosci. 1999;11:3767-3776.
138. Wasterlain CG, Liu H, Mazarati AM, et al. Self-sustaining status epilepticus: a condition maintained by potentiation of glutamate receptors and by plastic changes in substance P and other peptide neuromodulators. Epilepsia. 2000;41(suppl 6):134-143.
139. Niebauer M, Guenthal M. Topiramate reduces neuronal injury after experimental status epilepticus. Brain Res. 1999;837:263-269.
140. Andre V, Ferrandon A, Marescaux C, et al. Vigabatrin protects against hippocampal damage but is not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy. Epilepsy Res. 2001;47: 99-117.
141. Toivo H, Nissinen J, Pitkanen A. Effect of lamotrigine treatment on status epilepticus-induced neuronal damage and memory impairment in rat. Epilepsy Res. 2001;46:205-223.
142. Reibel S, Andre V, Chassagnon S, et al. Neuroprotective effects of chronic estradiol benzoate treatment on hippocampal cell loss induced by status epilepticus in the female rat. Neurosci Lett. 2000;281:79-82.
143. Veliskova J, Velisek L, Galanopoulou AS, et al. Neuroprotective effects of estrogens on hippocampal cells in adult female rats after status epilepticus. Epilepsia. 41(suppl 6):30-35, 2000.
144. Fujikawa DG. Neuroprotective effect of ketamine administered after status epilepticus onset. Epilepsia. 1995;36:186-195.
145. Shaner DM, McCurdy SA, Herring MO, Gabor AJ. Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin. Neurology. 1988;38:202-207.
146. Löhr A Jr., Weneck LC. Estudo comparativo nio randomizado do midazolam versus thiopental em crianças com estado de mal epilétptico refractário. Ar Qneuropsiquiatr. 2000;58:282-287.